Beyond The m⁷G Cap: How Non-Canonical RNA Capping Could Expand RNA Therapeutics

By Hana Cahová, Ph.D., Group Leader, Czech Academy of Sciences

For decades, RNA scientists viewed the 5’ cap through a remarkably narrow lens. The canonical 7-methylguanosine (m⁷G) cap was considered the defining feature of eukaryotic messenger RNA, a molecular “passport” that protects transcripts from degradation, promotes translation, and helps distinguish self from non-self. It became one of the foundational design elements of modern mRNA therapeutics, where optimizing cap chemistry has been instrumental in improving stability, protein expression, and manufacturing consistency.

Today, however, our understanding of RNA capping is undergoing a profound transformation. Over the past decade, researchers have uncovered an expanding collection of naturally occurring non-canonical RNA caps across bacteria, archaea, and eukaryotes. Rather than representing biological curiosities, these discoveries suggest that cells possess a far richer and more dynamic RNA regulatory system than previously appreciated. Molecules once considered purely metabolic cofactors — including NAD, FAD, coenzyme A, UDP-glucose, ADP-ribose, and dinucleoside polyphosphates — can also function as RNA caps, influencing RNA stability, processing, cellular localization, immune recognition, and degradation.

For developers of RNA therapeutics, this expanding biology raises an intriguing question: Could the next generation of RNA medicines rely on cap structures that extend beyond the canonical m⁷G cap?

The Cap Is More Than A Protective Structure

When most scientists think about RNA capping, they think about protecting messenger RNA. That perspective remains correct but incomplete.

The canonical m⁷G cap performs multiple functions simultaneously. It protects transcripts from exonucleases, recruits translation initiation factors, supports nuclear export, and helps cells recognize endogenous RNA. These properties explain why cap optimization became such a critical component of therapeutic mRNA development.

Yet the discovery of non-canonical caps reveals that nature has evolved numerous additional mechanisms for controlling RNA behavior.

Instead of serving only as passive protective structures, many of these alternative caps appear to integrate cellular metabolism directly with RNA regulation. In other words, the metabolic state of a cell may influence which RNAs receive particular caps, while those caps, in turn, affect RNA fate.

This represents a significant conceptual shift. RNA is no longer simply a messenger carrying genetic information. It also becomes a molecular sensor capable of reflecting, and responding to, the physiological state of the cell.

A Diverse Family Of RNA Caps

The diversity of newly discovered caps is striking. Researchers have identified RNAs carrying:

• NAD caps
• FAD caps
• coenzyme A (CoA) caps
• UDP-glucose caps
• ADP-ribose caps
• dinucleoside polyphosphate (NpₙN) caps
• γ-methyl phosphate cap-like structures.

Each possesses distinct chemical properties, interacts with different processing enzymes, and appears to influence RNA metabolism in unique ways.  Some promote RNA stability under certain conditions, while others accelerate degradation. Several appear to influence pathogen biology or antiviral responses and others may function as regulatory signals linking metabolism with gene expression. Importantly, these caps are found across all domains of life, suggesting they represent evolutionarily conserved mechanisms rather than isolated biological exceptions.

Why Therapeutic Developers Should Care

At first glance, non-canonical caps may appear to be a topic for basic RNA biology. In reality, they could have meaningful implications for RNA engineering.

The RNA therapeutics field continues to optimize nearly every component of therapeutic transcripts, including untranslated regions, codon usage, nucleotide chemistry, poly(A) tails, purification strategies, and delivery systems. The 5′ cap is another important engineering variable.

Today's therapeutic mRNAs primarily rely on optimized versions of the canonical cap because decades of research have established its role in efficient translation. But future RNA medicines may require more specialized performance characteristics.

For example, developers increasingly seek ways to:

• extend protein expression
• fine-tune translation kinetics
• reduce innate immune activation
• improve tissue-specific activity
• enable repeated dosing.

A broader understanding of natural RNA cap biology could eventually provide new strategies for addressing these challenges. Rather than relying on a single cap architecture, future therapeutic platforms may incorporate cap designs tailored to the biological requirements of specific indications.

RNA Caps And Innate Immunity

Immune recognition represents another area of growing interest. One reason cap chemistry became central to mRNA vaccine development is that cells use RNA structural features to distinguish endogenous RNA from foreign RNA. Non-canonical caps add additional complexity to this process.

Several metabolite-derived caps interact differently with innate immune sensors than canonical mRNA. Some viral RNAs exploit unusual cap structures to evade host immunity, while others appear to trigger distinct antiviral pathways. The precise biological consequences remain an active area of investigation, but these findings underscore that cap chemistry influences far more than translation efficiency alone.

For therapeutic developers, this suggests that future cap engineering could become another tool for modulating immunogenicity in applications ranging from vaccines to protein replacement therapies.

Analytical Challenges Remain

Expanding the catalog of RNA caps also presents new analytical demands. Unlike canonical caps, many non-canonical structures exist at low abundance and require specialized analytical methods for detection and characterization. Advances in mass spectrometry, enzymatic assays, and next-generation sequencing are beginning to make these studies possible, but standardized analytical workflows remain under development.

As RNA therapeutics continue to mature, robust analytical platforms will be essential not only for understanding natural RNA biology but also for evaluating future engineered cap designs.

The Next Frontier In RNA Engineering

Many of the most important innovations in RNA therapeutics have emerged from studying natural biology. Modified nucleosides, lipid nanoparticles, circular RNA, and self-amplifying RNA all draw inspiration from mechanisms that evolved long before therapeutic applications existed. Non-canonical RNA capping may represent another example.

Much remains unknown. The biological roles of many alternative caps are still being defined, and their potential value for therapeutic RNA engineering has yet to be fully explored. Nevertheless, their discovery has fundamentally expanded our understanding of RNA regulation and challenged the long-standing assumption that the canonical m⁷G cap is the only biologically meaningful solution.

For RNA therapeutics, the message is clear: as we continue to optimize every element of RNA design, the future of the field may depend not only on better delivery systems or more sophisticated sequence engineering but also on rethinking one of RNA biology's oldest and most familiar features — the 5’ cap itself.

About The Author

Hana Cahová, Ph.D., is a group leader in the Chemical Biology of Nucleic Acids Laboratory at the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague). Her research focuses on the chemistry and biology of RNA, with particular emphasis on RNA modifications, non-canonical RNA caps, RNA metabolism, and the development of chemical biology tools to study nucleic acids. Her laboratory combines synthetic chemistry, mass spectrometry, next-generation sequencing, and molecular biology to investigate how RNA modifications regulate cellular and viral processes. Cahová has authored numerous high-impact publications and is internationally recognized for her contributions to the discovery and characterization of novel RNA modifications and RNA capping mechanisms.